x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DCL-001030
| Product Information | |
|---|---|
| Parental | THP-1 |
| Organism | Human |
| Tissue | Blood |
| Target Name | TCF7L2 |
| Cell Type | Acute monocytic leukemia |
| Gender | Male |
| UniProt No. | Q9NQB0 |
| Gene ID | 6934 |
| Gene Description | Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. |
| Format | Frozen |
| Growth Properties | Suspension |
| Shipping & Storage | |
|---|---|
| Shipping | Cryopreserved on dry ice. |
| Storage Instructions | Store in liquid nitrogen. |
| Storage Buffer/Media | 8.7% Dimethylsulfoxide, 2% Cellulose, methyl ether |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
